YOLFTbeta
Shanghai Medicilon Inc

Shanghai Medicilon Inc

688202 · SHG · Healthcare / Biotechnology

75.56CNY-4.54 (-5.67%)

Price History

Full chart

Market Stats

Previous Close80.10
Open79.32
Day Range74.88 – 79.32
52-Week Range50.50 – 120.00
Volume5.06M
Market Cap14.46B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.78
Dividend Yield0.00%
Beta0.76
50-Day Avg96.08
200-Day Avg72.91

About

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology services. The company also provides peptide, SiRNA, ADC, Protac, AOCs, NAMs Platforms. The company was founded in 2004 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Chun-Lin Chen Ph.D.
  • Employees2.78K
  • HeadquartersNo. 585, Chuanda Road, Shanghai, China, 201299, China
  • Websitehttps://www.medicilon.com.cn

Leadership

  • Dr. Chun-Lin Chen Ph.D.Co-Founder, Chairman & CEO · b. 1962
  • Mr. Shuangqing Peng Ph.D.Chief Scientific Officer · b. 1962
  • Dr. Jinna Cai Ph.D.Chief Commercial Officer, Deputy GM & Director · b. 1964
  • Ms. Binbin LiuDeputy General Manager · b. 1977
  • Mr. Jianglin HuJoint CEO, Executive VP & Chief Strategy and Development Officer · b. 1970
  • Ms. Donghua ZhangFinancial Director · b. 1985
  • Fang Hong ChenAccounting Supervisor
  • Dr. Lilly Xu Ph.D.Chief Technology Officer
  • Ms. Jiang Xu MBAManager of Human Resources Department
  • Dr. Haizhou ZhangPresident of Preclinical R&D Unit

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue232.32M249.27M324.94M449.39M665.96M1.17B1.66B1.37B1.04B1.16B
Growth (%)-+7.30%+30.35%+38.30%+48.19%+75.28%+42.12%-17.68%-24.01%+12.08%
Cost of Revenue148.22M163.76M205.75M287.99M392.43M638.04M982.31M1.04B972.27M961.18M
Gross Profit84.10M85.51M119.19M161.40M273.53M529.22M676.62M324.61M65.47M201.88M
Gross Margin36.20%34.30%36.68%35.92%41.07%45.34%40.79%23.77%6.31%17.36%
Operating Expense37.43M36.81M51.59M85.82M125.00M197.79M294.88M318.47M281.90M299.63M
Operating Income46.67M48.70M67.61M75.58M148.52M331.43M381.74M6.14M-216.43M-97.75M
Operating Margin20.09%19.53%20.81%16.82%22.30%28.39%23.01%0.45%-20.86%-8.40%
EBITDA-61.02M79.41M91.56M170.62M383.42M452.22M54.22M-261.41M-65.02M
EBITDA Margin-24.48%24.44%20.37%25.62%32.85%27.26%3.97%-25.19%-5.59%
Net Income43.41M41.62M60.77M66.57M129.39M282.22M338.24M-33.21M-330.85M-167.83M
Net Income Margin18.68%16.70%18.70%14.81%19.43%24.18%20.39%-2.43%-31.88%-14.43%
R&D9.30M11.08M16.52M28.19M46.96M77.76M122.88M122.39M96.73M104.41M
R&D as % of Total Revenue4.00%4.44%5.08%6.27%7.05%6.66%7.41%8.96%9.32%8.98%
Interest Expense005.47M4.80M8.06M2.01M4.88M9.66M8.36M9.51M
Interest Expense % of Total Revenue0.00%0.00%1.68%1.07%1.21%0.17%0.29%0.71%0.81%0.82%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets344.90M389.61M472.95M1.13B1.36B1.79B2.33B3.27B2.82B2.62B
Total Liabilities98.81M102.29M125.06M127.73M228.67M466.06M726.80M755.07M683.10M687.85M
Total Equity243.25M283.42M342.40M993.05M1.12B1.33B1.60B2.51B2.14B1.93B
Cash144.12M156.82M166.55M636.29M465.95M412.37M197.13M471.87M260.53M286.78M
Net Debt------52.06M-52.70M-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow34.13M74.70M71.11M58.30M207.77M452.94M-21.33M33.32M-22.75M105.17M
Investing Cash Flow-31.39M-58.91M-64.37M-168.16M-371.60M-399.55M----
Financing Cash Flow-579.23M579.23M579.23M-1.90M-105.97M----
Capital Expenditure39.31M58.91M64.37M97.38M118.72M292.71M404.06M300.10M110.39M69.03M
Free Cash Flow-15.79M6.73M-39.08M89.05M160.22M-425.39M-282.79M-133.14M36.14M
Dividends Paid830.46K-39.06M39.06M39.06M39.06M87.33M40.95M6.97M7.42M
FCF to OCF-21.14%9.47%-67.03%42.86%35.37%1994.24%-848.74%585.29%34.36%
Dividend Paid to FCF--580.12%-99.95%43.86%24.38%-20.53%-14.48%-5.24%20.54%

Earnings

Report DateOct 17, 2019Mar 30, 2020Apr 24, 2020Aug 17, 2020Oct 27, 2020Feb 25, 2021Apr 23, 2021Aug 10, 2021Oct 29, 2021Feb 25, 2022Apr 28, 2022Aug 22, 2022Oct 30, 2022Feb 20, 2023Apr 25, 2023
EPS Estimate0.00--------------
EPS Actual0.580.230.250.360.320.630.730.780.781.170.890.981.330.691.17
Surprise---------------
Timing-After-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap14.46B
Enterprise Value15.47B
Trailing P/E0.00
Forward P/E0.00
Price / Sales10.45
Price / Book7.85
EPS-0.78
Book Value14.89
Revenue (TTM)1.38B
Gross Profit (TTM)321.45M
EBITDA-13.99M
Profit Margin-7.47%
Operating Margin10.23%
Return on Equity-5.06%
Return on Assets-2.33%
Shares Outstanding134.35M
Shares Float77.42M
Beta0.76
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.39Jun 2, 2023
20221×
0.98Jun 8, 2022
20211×
0.32Jun 3, 2021

Stock Splits

  • Jun 2, 20231.4:1
  • Jun 8, 20221.4:1